At last, a pill that can prevent COVID after exposure to infected people

Drug arrives years after pandemic’s peak, but could still offer protection to vulnerable populations.

Email Bluesky Facebook LinkedIn Reddit Whatsapp X Access through your institution Buy or subscribe An antiviral pill has, for the first time, been shown to prevent COVID-19 in people exposed to the SARS-CoV-2 virus at home, according to trial results published today in the New England Journal of Medicine 1 . Access options Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 52 print issues and online access $199.00 per year only $

related reading

• How antiviral pill molnupiravir shot ahead in the COVID drug huntnature.com
• Scientists make breakthrough towards ‘universal’ antiviral drugsgavi.org
• COVID-19 drug discovery and treatment options | Nature Reviews Microbiologynature.com
• The trinity of COVID-19: immunity, inflammation and interventionnature.com
• What most surprised experts about the Covid pandemic | STATstatnews.com
• Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children - PubMedpubmed.ncbi.nlm.nih.gov
• How to (ab)use a COVID-19 antigen rapid test with soft drinks? - PubMedpubmed.ncbi.nlm.nih.gov
• Long COVID is devastating and far from rare. As infections rise again, why are we still ignoring it? - Salon.comsalon.com
• Why were Covid vaccine trials so fast?substack.com
• Cannabis Use Is Associated With Lower COVID-19 Susceptibility but Poorer Survivalncbi.nlm.nih.gov
• CG-dinucleotide suppression enables antiviral defense targeting non-self RNA - PMCncbi.nlm.nih.gov
• New HIV vaccine shows unprecedented success in preclinical study – lji.orglji.org